Brokerages Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $21.43

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus recommendation of “Hold” by the seventeen brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $22.80.

Several analysts recently weighed in on HIMS shares. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th.

Hims & Hers Health Stock Down 0.6 %

HIMS stock opened at $26.20 on Monday. The company’s 50-day moving average price is $25.78 and its two-hundred day moving average price is $21.27. The firm has a market cap of $5.72 billion, a P/E ratio of 59.55 and a beta of 1.25. Hims & Hers Health has a 12 month low of $8.09 and a 12 month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.04) earnings per share. Equities analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity

In other news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the transaction, the chief financial officer now directly owns 145,763 shares of the company’s stock, valued at $2,960,446.53. The trade was a 64.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 78,127 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74. Following the sale, the chief executive officer now directly owns 109,956 shares of the company’s stock, valued at $3,256,896.72. This represents a 41.54 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,085,157 shares of company stock valued at $26,765,193. 17.71% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Principal Financial Group Inc. grew its holdings in Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after purchasing an additional 146,621 shares during the period. Sanctuary Advisors LLC grew its stake in shares of Hims & Hers Health by 26.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company’s stock valued at $480,000 after buying an additional 5,505 shares during the period. Neo Ivy Capital Management bought a new stake in Hims & Hers Health in the 3rd quarter valued at about $1,252,000. Geode Capital Management LLC boosted its holdings in Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Finally, Barclays PLC grew its stake in Hims & Hers Health by 9.7% in the third quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after acquiring an additional 27,231 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.